The U.S -based InVita Healthcare Technologies has recently announced investing an undisclosed amount in STACS DNA, a prominent leader in sexual assault kit tracking and software provider.
For the record, the products delivered by STACS DNA are generally used by leading forensic DNA labs in North America.
STACS DNA stays committed to serving the forensic market, as it has been doing for more than 20 years. However, parallelly, it can now expand its presence into the healthcare market with its STACS laboratory information management system and Track-Kit for tracing sexual assault kits and newborn screening specimens.
It has been claimed that the solutions are trusted by thousands of users at government agencies, hospitals, laboratories, and other shareholders to monitor samples, enhance information-sharing, and manage inventory.
Speaking on the latest accomplishment, President and CEO of InVita, Todd Collins quoted that the organization is thrilled to welcome STACS DNA and its world-class suite of an expansive portfolio of solutions for complex medical environments.
Todd further mentioned that deploying forensic and healthcare DNA sample tracking into the company’s offerings supports InVita’s mission of providing the most innovative and holistic solutions or managing intricate medical workflows for its clients. Moreover, the company is proud to be working with the leader in this space.
Meanwhile, President and CEO of STACS DNA, Jocelyn Tremblay cited that the firm is excited to be a part of InVita and through this partnership, STACS DNA is looking forward to leveraging its forensics-grade sample tracing solutions inside the lab.
Mr. Tremblay suggested that the solutions are likely to improve patient safety, alleviate the risk related to medical laboratory testing, while simultaneously increasing the productivity.
For the uninitiated, InVita offers exceptional healthcare technologies for complex medical settings. Its solutions seek to optimize the supply chain performance and visibility for plasma, implants, blood, and beyond.
© 2024 IntelligenceJournal.com. All Rights Reserved.